Fuse launches Flip Mycoplasma in Europe in partnership with CliniSciences
Fuse Diagnostics (Fuse) has today announced that it has launched Flip Mycoplasma in Europe and signed a distribution agreement with CliniSciences covering major European countries, including France, Germany, Spain and Italy.
Flip Mycoplasma is a revolutionary new test that detects cell culture contamination with unrivalled speed, accuracy and simplicity. It delivers laboratory PCR quality results in just 12 minutes in a simple, single-use format, enabling ultra-rapid detection of Mycoplasma contamination in cell cultures.
Flip Mycoplasma is provided in a ready-to-use format and exhibits exceptional diagnostic performance giving a clear visual result read-out in just minutes without any complex equipment or processing. It empowers end users to eliminate reproducibility and quality issues in cell biology research and bioprocessing - saving valuable time and reducing costs.
Fuse CEO Dr Harry Lamble said: “We are delighted to make available our transformative solution for Mycoplasma contamination across Europe. We look forward to working with CliniSciences to ensure our test is brought to the maximum possible number of end users so they can overcome the delay and complexity of existing centralised instrument-based tests.”
In August Fuse announced the launch of Flip Mycoplasma in UK and Ireland in partnership with Stratech Scientific. Fuse’s distribution agreement with CliniSciences covers all of the major European countries (excluding UK and Ireland).
ENDS
Notes for editors
Fuse Diagnostics is focused on delivering laboratory-quality diagnostic information wherever it is needed through innovative, rapid, low-cost tests – addressing the cost and performance challenges of established approaches. The company is developing a revolutionary new generation of multianalytic diagnostic products, based on its Flip and Apex platforms, to make accurate point-of-need testing a reality for all. Fuse founders Harry and Ralph Lamble previously founded Sense Biodetection where they developed the world’s first rapid instrument-free, molecular diagnostic test (Veros COVID-19) during the pandemic. Following the acquisition of Sense by Sherlock Biosciences in 2023, the brothers decided to apply their experience of clinical product development and commercialisation to address the widespread demand for rapid onsite pathogen testing across industry.
Flip Mycoplasma is a new test for mycoplasma contamination in cell culture that allows users to screen their cultures, cell lines and reagents with unrivalled speed, accuracy and simplicity. It is highly accurate and targets 16S ribosomal RNA for robust specificity, delivering the performance of laboratory PCR in just minutes. It is simple to use, with ambient storage and is provided in a ready-to-use format. Samples can be tested directly without processing and the test gives a clear visual result readout. Flip Mycoplasma is a versatile solution, compatible with any standard heat block or PCR machine, or the USB-C powered Flip Nest, and allows users to perform rapid molecular quality testing in any location without complex equipment or procedures.
CliniSciences is a leading European distributor for life science and diagnostic labs. As a recognized distributor in the scientific research and diagnostics sector, CliniSciences positions itself as a key player linking manufacturers of quality products worldwide with researchers in Europe and North America. CliniSciences is positioned to serve both customers and manufacturers:
Customers, by meeting their needs in fields as varied as cell biology, immunology, oncology, biochemistry and plant research.
Manufacturers, by acting as a local intermediary to help them identify and interact with potential customers.